| Species |
Human |
| Protein Construction |
IL-8/CXCL8 (Ser28-Ser99)
Accession # P10145-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-8/CXCL8, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiIL8 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
9.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 11-13 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms. |
| Synonyms |
Interleukin-8; IL-8; GCP-1; MDNCF; MONAP; NAP-1; GCP/IL-8 protein IV; IL8/NAP1 form I; CXCL8; LECT; LUCT; LYNAP; NAF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
